| House Positions for C:EDT from 20240401 to 20240401 |
| 79 CIBC | 11,070 | 5,202 | 0.47 | 4,500 | 2,115 | 0.47 | 6,570 | -3,087 |
| 1 Anonymous | 7,500 | 3,397 | 0.453 | 2,070 | 957 | 0.462 | 5,430 | -2,440 |
| 14 Virtu ITG | 100 | 44 | 0.44 | 0 | | 100 | -44 |
| 80 National Bank | 77 | 34 | 0.442 | 77 | 34 | 0.442 | 0 | 0 |
| 85 Scotia | 2,000 | 920 | 0.46 | 2,600 | 1,157 | 0.445 | -600 | 237 |
| 7 TD Sec | 2,000 | 940 | 0.47 | 5,000 | 2,285 | 0.457 | -3,000 | 1,345 |
| 2 RBC | 0 | | 8,500 | 3,990 | 0.469 | -8,500 | 3,990 |
| TOTAL | 22,747 | 10,537 | 0.463 | 22,747 | 10,538 | 0.463 | 0 | 1 |
Interesting today how light the Volume was especially with a couple Headlines on Yahoo Finance & Simply Wallstreet saying
Maybe the Smart Money knows it's Only A SMOKESCREEN and if we get any kind of a Significant Pullback it's a SCREAMING BUY!
Even at this Price it's a BUY BUY BUY!!
Not Pumping....Just Read The Recent Analyst Report for yourself! Came out March 14th.
We should easily be over $1.00 a Share but we are just a small unknown Canadian Company with very little US News Exposure. Yet Baxter knows EXACTLY what they have!
A Huge Winner with an Annual 2 Billion Dollar Potential Market not to mention the other potential medical uses for PMX.
The increase of $ 3,254,000 (excluding investment loss and impairment) was due primarily to increased consulting and professional services majorly due to increased site and patient fees related to the Tigris trial and Eden observational study; THATS WHY OUR ENROLMENT PACE HAS PICKED UP!!
Everything Costs Money and especially Professional Medical Related Services for Trials.
The Financing is needed as EVERY FDA Trial costs money and seeing we are in the final stretch the Financing is a NO BRAINER with BAXTER likely taking most of it and it's probably already done!
We are at 97 Patients and the enrolment will increase as New Trial Sites come on. Simple Math!
Still Very REVED UP!
Cheers!